Genscript Biotech Statistics
Genscript Biotech (G51) Stock Statistics & Valuation Metrics
Total Valuation
Genscript Biotech has a market cap or net worth of EUR 8.77B. The enterprise value is EUR 22.93B.
- Market Cap
- EUR 8.77B
- Enterprise Value
- EUR 22.93B
Share Statistics
Genscript Biotech has 2,284,025,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,284,025,600
- Owned by Insiders
- ―
- Owned by Institutions
- 9.73%
Financial Efficiency
Genscript Biotech’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is 5.54%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- 5.54%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 156.40K
- Profits Per Employee
- -86.85K
- Employee Count
- 6,135
- Asset Turnover
- 0.20
- Inventory Turnover
- 10.26
Valuation Ratios
The current PE Ratio of Genscript Biotech is -13.66. Genscript Biotech’s PEG ratio is 0.00.
- PE Ratio
- -13.66
- PS Ratio
- 10.87
- PB Ratio
- 2.29
- Price to FCF
- 182.41
- Price to Operating Cash Flow
- 59.59
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Genscript Biotech had revenue of 959.53M and earned -532.83M in profits. Earnings per share was -0.25.
- Revenue
- 959.53M
- Gross Profit
- 553.20M
- Operating Income
- 255.25M
- Pretax Income
- -470.53M
- Net Income
- -532.83M
- EBITDA
- 329.29M
- Earnings Per Share (EPS)
- -0.25
Cash Flow
In the last 12 months, operating cash flow was 149.59M and capital expenditures -99.29M, giving a free cash flow of 50.30M billion.
- Operating Cash Flow
- 149.59M
- Free Cash Flow
- 50.30M
- Free Cash Flow per Share
- 0.02
Dividends & Yields
Genscript Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.52%
- Earnings Yield
- -6.76%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- 112.79%
- 50-Day Moving Average
- 4.07
- 200-Day Moving Average
- 2.22
- Relative Strength Index (RSI)
- 48.24
- Average Volume (3m)
- 400
Important Dates
Genscript Biotech upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Genscript Biotech as a current ratio of 1.47, with Debt / Equity ratio of 6.54%
- Current Ratio
- 1.47
- Quick Ratio
- 1.41
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 0.26
- Interest Coverage Ratio
- 14.74
Taxes
In the past 12 months, Genscript Biotech has paid 61.87M in taxes.
- Income Tax
- 61.87M
- Effective Tax Rate
- -0.13
Enterprise Valuation
Genscript Biotech EV to EBITDA ratio is 47.42, with an EV/FCF ratio of 193.53.
- EV to Sales
- 11.53
- EV to EBITDA
- 47.42
- EV to Free Cash Flow
- 193.53
- EV to Operating Cash Flow
- 65.07
Balance Sheet
Genscript Biotech has EUR 831.18M in cash and marketable securities with EUR 254.68M in debt, giving a net cash position of EUR 576.50M billion.
- Cash & Marketable Securities
- EUR 831.18M
- Total Debt
- EUR 254.68M
- Net Cash
- EUR 576.50M
- Net Cash Per Share
- EUR 0.25
- Tangible Book Value Per Share
- EUR 1.78
Margins
Gross margin is 51.99%, with operating margin of 14.88%, and net profit margin of -75.40%.
- Gross Margin
- 51.99%
- Operating Margin
- 14.88%
- Pretax Margin
- -69.85%
- Net Profit Margin
- -75.40%
- EBITDA Margin
- 24.32%
- EBIT Margin
- 14.88%
Analyst Forecast
The average price target for Genscript Biotech is EUR 4.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 4.96
- Price Target Upside
- 31.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- 43.29%
- EPS Growth Forecast
- -118.54%
Scores
- Smart Score
- 10
- AI Score
- ―
